The REinfection in COVID-19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers.
Influenza Other Respir Viruses
; 16(5): 916-925, 2022 09.
Article
in English
| MEDLINE | ID: covidwho-1819906
ABSTRACT
BACKGROUND:
Understanding the immune response to natural infection by SARS-CoV-2 is key to pandemic management, especially in the current context of emerging variants. Uncertainty remains regarding the efficacy and duration of natural immunity against reinfection.METHODS:
We conducted an observational prospective cohort study in Canadian healthcare workers (HCWs) with a history of PCR-confirmed SARS-CoV-2 infection to (i) measure the average incidence rate of reinfection and (ii) describe the serological immune response to the primary infection.RESULTS:
Our cohort comprised 569 HCWs; median duration of individual follow-up was 371 days. We detected six cases of reinfection in absence of vaccination between August 21, 2020, and March 1, 2022, for a reinfection incidence rate of 4.0 per 100 person-years. Median duration of seropositivity was 415 days in symptomatics at primary infection compared with 213 days in asymptomatics (p < 0.0001). Other characteristics associated with prolonged seropositivity for IgG against the spike protein included age over 55 years, obesity, and non-Caucasian ethnicity.CONCLUSIONS:
Among unvaccinated healthcare workers, reinfection with SARS-CoV-2 following a primary infection remained rare.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
Type of study:
Cohort study
/
Diagnostic study
/
Observational study
/
Prognostic study
Topics:
Vaccines
/
Variants
Limits:
Humans
/
Middle aged
Country/Region as subject:
North America
Language:
English
Journal:
Influenza Other Respir Viruses
Journal subject:
Virology
Year:
2022
Document Type:
Article
Affiliation country:
Irv.12997
Similar
MEDLINE
...
LILACS
LIS